

FOR IMMEDIATE RELEASE

IntegraGen Announces 17% Increase in Sales Revenue and a 57% Increase in Operating Profit for the First Half of 2018

Financial results:

- Sales revenue: 3.7 M€, +17% vs. H1 2017
- Significant growth in genomics services
- Operating profit: -0.5 M€, + 57% vs. H1 2017

Main Operational Advances:

- Significant growth in genomics activities, driven by the research segment.
- The Sequencing Omics Information Analysis (SeqOIA) Cooperative Health Group (GCS), comprised of the AP-HP, Institut Curie and Gustave Roussy, announced IntegraGen has been selected for a contract in the amount of 16 M€ to 25 M€ over five years for the operation of high-throughput sequencing platform
- Commercialization of SIRIUS™ and MERCURY™ genomic interpretation software tools as part of a global distribution agreement with Twist Biosciences.
- First North American licensing agreement for miR-31-3p with GoPath Laboratories.

Evry, FRANCE (September 20, 2018, 6:30pm cest) - IntegraGen (FR0010908723: ALINT - PEA-SME Eligible), a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company's Board of Directors on September 20, 2018.

KEY INDICATORS – in thousands of euros	H1 2018 (6 months)	H1 2017 (6 months)	Var. %
Revenue	3 624	3 089	+17%
Total revenue	3 725	3 294	+13%
Operating profit	- 539	-1 248	+57%
Net results	-545	-480	-14%

	30 June 2018	31 December 2017
Cash position – in thousands of euros	3 320	4 132

Bernard Courtieu, President and CEO of IntegraGen stated: "The significant improvement in financial results, combined with the major operational improvements achieved over the half-year, confirm the trend, observed in 2017, of improved profitability and the development of all our business lines. These advances enable us to aim for the achievement of the breakeven point by 2020. As announced last July, the choice of the GCS SeqOIA group to allocate the operation of the high-throughput sequencing platform to IntegraGen for a five-year term confirms our leadership in genomics and allows us to take a major economic step forward for the company."

- **Income Statement**

Sales for the first half of 2018 were up 17% to 3,624 K€ compared to 3,089 K€ for the same period in 2017. After taking into account operating subsidies, depreciation and provisions, operating income amounted to 3,725 K€ compared to 3,294 K€ in the first half of 2017, an improvement of 13%.

Operating expenses totaled 4,264 K€, down 6% compared to the first half of 2017. This reduction was mainly due to the end of the costs associated with the CE mark project for the miRpredX kit which was completed in September 2017. Operational productivity continues to improve with stable reagent costs in parallel with an 20% increase in activity.

Operating income was therefore a loss of 539 K€ during the first half of 2018 compared to a loss of 1,248 K€ in the first half of 2017, an improvement of 57%.

The Company recorded an **extraordinary result** of -104 K€ during the period.

After taking into account the financial and extraordinary results along with the Research Tax Credit (CIR) related to the research work carried out during the period, the **net result** showed a loss of 545 K€, against a loss of 480 K€ during the first half of 2017. This 13% decrease was primarily due to non-recurring items (BPI waiver in particular) in the previous half-year.

- **Balance Sheet**

At the end of June 2018, IntegraGen's **net cash** amounted to 3,320 K€ compared to 4,132 K€ at the end of December 2017.

ACTIVITIES

- **Genomic Services**

Revenue from genomic services totaled 3,584 K€ as June 30, 2018, up 20% compared to the first half of 2017. The increase was particularly pronounced in the research segment with sales increasing 42%.

Additionally, on July 27, 2018, the SeqOIA Cooperative Health Group (GCS), which includes the AP-HP, Gustave Roussy and the Institut Curie, announced that it had selected the offer of IntegraGen, with official notification of the contract on August 30, 2018. As a result of this contract, IntegraGen will operate the GCS high-throughput sequencing platform for the next five years as part of the France Genomics 2025 plan. This contract has a guaranteed minimum of 16.4 million euros (up to 25.4 million euros).

- **Software**

IntegraGen announced in February 2018 that the company had signed a worldwide licensing agreement with Twist Bioscience enabling Twist to commercialize SIRIUS and MERCURY. According to the terms of this agreement, Twist Bioscience, which produces and sells exome capture kits, will be able to offer IntegraGen's software tools for the interpretation of sequencing data resulting from the use of their kits.

- **Diagnostic**

IntegraGen continued its development and commercialization of the miR-31-3p biomarker during the first half of 2018, including the first North American licensing agreement with GoPath Laboratories as well as several scientific publications and communications. GoPath Labs, with IntegraGen's support,

obtained a Proprietary Laboratory Analysis (PLA) billing code from the American Medical Association (AMA) which specifically identifies the miR-31-3p test and supports the filing of claims for test reimbursement by insurers in the U.S.

Sales amounted to 40 K€ in the first half of 2018 which primarily consisted of royalties associated with licensing agreements.

ABOUT INTEGRAGEN

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2017, IntegraGen had 40 employees and had generated revenue of €6.1 million in 2017. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit www.integragen.com



INTEGRAGEN CONTACTS

IntegraGen

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00

NewCap

Investor and Media Relations
Louis-Victor DELOUVRIER
integragen@newcap.eu
Tel.: +33 (0)1 44 71 98 53

FINANCIALS AS OF JUNE 30, 2018

P&L – INTEGRAGEN SA

<i>in K€</i>	30/06/2018	30/06/2017	Var. %
Revenues	3 624	3 089	+17%
Operating subsidies and other revenues	102	206	(50%)
Total Revenues	3 726	3 294	+13%
Operating costs	(4 264)	(4 542)	(6%)
Operating profit	(539)	(1 248)	+57%
Financial Profit/Loss	(4)	21	
Current result	(542)	(1450)	+62%
Exceptional Profit/Loss	(104)	498	
Taxes (CIR)	101	249	(59%)
Net result	(545)	(480)	(14%)

BALANCESHEET – INTEGRAGEN SA

<i>In K€</i>	30/06/2018	31/12/2017
Long-Term Assets	662	738
Stocks	309	360
Accounts Receivable	1 898	2 410
Other Receivables	689	1 005
Cash	3 320	4 132
Current Assets	6 218	7 907
Translation difference	7	0
TOTAL ASSETS	6 887	8 645

<i>In K€</i>	30/06/2018	31/12/2017
Shareholders' Equity	3 388	3 930
Other Equity	435	540
Contingency	84	12
Notes payable to banks	0	0
Accounts Payable	2 018	2 440
Other short-term debts	961	1 718
Translation difference	1	5
TOTAL LIABILITIES	6 887	8 645